Investigational Drug Information for Latrepirdine
✉ Email this page to a colleague
What is the drug development status for Latrepirdine?
Latrepirdine is an investigational drug.
There have been 8 clinical trials for Latrepirdine.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2009.
The most common disease conditions in clinical trials are Alzheimer Disease, Huntington Disease, and [disabled in preview]. The leading clinical trial sponsors are Medivation, Inc., Pfizer, and [disabled in preview].
Summary for Latrepirdine
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 855 |
| WIPO Patent Applications | 548 |
| Japanese Patent Applications | 316 |
| Clinical Trial Progress | Phase 1 (2009-10-01) |
| Vendors | 43 |
Recent Clinical Trials for Latrepirdine
| Title | Sponsor | Phase |
|---|---|---|
| An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease | Medivation, Inc. | Phase 3 |
| An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease | Pfizer | Phase 3 |
| An Extension of the CONCERT Protocol (DIM18) | Pfizer | Phase 3 |
Clinical Trial Summary for Latrepirdine
Top disease conditions for Latrepirdine
Top clinical trial sponsors for Latrepirdine
US Patents for Latrepirdine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
